MI-EATON
Intelligent power management company Eaton today announced its eMobility business is now offering specialized high-power lock box (HPLB) power connectors for use in current and future electrified and internal combustion vehicle solutions. The HPLB connectors, a component of eMobility’s Power Connections portfolio, offer a space-saving profile, superior performance, cost savings and reduced manufacturing complexity. The HPLB connectors were designed and developed by Royal Power Solutions, a leading manufacturer of high-precision electrical connectivity components that Eaton acquired in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005136/en/
Eaton’s specialized high-power lock box (HPLB) terminal system forms a connection in a unique way that provides improved contact force throughout the component’s service life. (Photo: Business Wire)
HPLB connectors provide protection against the elements, corrosion
“Eaton recommends use of sealed connection systems to meet reliability and durability requirements,” said Chris Mancuso, general manager, Power Connections, Eaton. “Additionally, we’ve designed our HPLB terminal system for high-current and high-temperature applications, up to 500 amps and 125 degrees Celsius, respectively.”
Traditionally, eyelet terminals within vehicle electrical components are not sealed, potentially exposing them to road spray and salt, which accelerates terminal galvanic corrosion. Corrosion can mitigate the power flow, leading to system failure.
The fully sealed connectors are also resistant to severe vibration and deliver a component service life that meets USCAR Safety Performance Requirements.
Innovative terminal contact methodology
Eaton’s HPLB terminal system forms a connection in a unique way that provides improved contact force throughout the component’s service life. Unlike traditional box and blade terminals, the connectors use Power Connections’ Connector Positive locks, which utilize an “inside-out” contact system with internal spring pressure and multiple contact points. The unique configuration provides a stronger connection than that of conventional box-and-blade connectors where the female terminal spring squeezes the male blade, which loosen when exposed to heat and vibration, resulting in a loss of power flow continuity and the possibility of corrosion.
“Power connectors, while a small component, are a critical design element to meet product performance and durability requirements,” Mancuso said. “Commercial fleet operators not only expect but require that all vehicle systems have a service life of at least 10 years.”
The unique connection also reduces heat radiating from the connection points by an average of six degrees Fahrenheit per contact. Many modern vehicles have up to 120 such contact points, so leveraging HPLB connectors leads to dramatic temperature mitigation and improved vehicle performance.
Reduces manufacturing complexity, potential for harmful production errors
Traditionally, eyelet terminals are manually connected by a production line worker wearing two sets of gloves for protection against high voltage and an air gun to tighten small nuts. If the connection is not precise every time it can result in a disruption in power flow. If the operator accidentally drops a nut into the component’s inner workings, it can short circuit the entire unit.
The HPLB connectors can be installed by a “pick-and-place” robot, allowing for precise and safe connections every time. Additionally, the HPLB sits flush, unlike traditional connector terminals, reducing space requirements within the vehicle.
“Our HPLB terminal connectors not only lower temperature, but provide extra current carrying capacity,” Mancuso said. “So, they are half the size and carry twice the current, and in some applications up to three times the current.”
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power — today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005136/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
